About the company iPROMOMED
Security pagePromomed is a Russian pharmaceutical company that develops and manufactures drugs for the treatment of obesity, diabetes, cancer and infectious diseases. Unlike pure generics manufacturers, it invests in its own developments. The shares trade under the ticker PRMD.
What the company does
The company operates in two modes at once, and this defines its economics. Part of the portfolio consists of generic drugs that generate revenue today. Part consists of in-house developments, which require years of investment and bring in money only after registration.
The bet is on therapeutic areas with growing demand: drugs for weight loss and diabetes treatment are one of the fastest-growing segments of global pharmaceuticals. Success here could change the scale of the company, while failure in research could wipe out the value of the years invested.
Production is the company's own, in Mordovia, which reduces dependence on contract manufacturing sites and gives control over quality and production timelines.
Business lines
Endocrinology
Drugs for diabetes treatment and weight loss — a fast-growing segment.
Oncology
Anticancer drugs, including those for government programmes.
Infectious diseases
Antiviral and antibacterial medicines.
Development
In-house research programmes and the registration of new drugs.
History
- 2005The company is founded, starting out in distribution and contract manufacturing.
- 2010-еLaunch of its own production in Mordovia and the move into drug development.
- 2024Share offering on the Moscow Exchange.
Business review
Strengths and weaknesses describe the business itself. Opportunities and threats describe what may happen around it.
Strengths
- A bet on endocrinology — one of the fastest-growing segments of global pharmaceuticals.
- In-house developments deliver a higher margin than generic drugs.
- In-house production ensures control over the timing and quality of output.
- Government drug provision programmes deliver stable demand.
Weaknesses
- Some developments never reach registration, and the years invested in them lose their value.
- The timing of registration procedures is outside the company's control and pushes back market entry.
- Active pharmaceutical ingredients are largely imported and sensitive to supply restrictions.
- Prices for vital medicines are regulated by the state.
Opportunities
- The replacement of imported medical devices widens the pool of customers.
- Government programmes for equipping hospitals finance the purchases.
- An ageing population increases the consumption of medical products.
- The exit of foreign manufacturers has freed up niches in the market.
Threats
- The registration of medical devices takes time and is not guaranteed.
- Raw materials and components are imported, and supplies are sensitive to restrictions.
- Hospital purchases follow the budget cycle rather than demand.
- Large manufacturers compete on price in the same tenders.
Frequently asked questions
What does the company Promomed do?
It develops and manufactures medicines: for the treatment of diabetes and obesity, cancer and infectious diseases. Production is located in Mordovia.
How does an original drug differ from a generic?
An original drug is created from scratch: the molecule is discovered, tested and registered, which takes years and a great deal of money, but in return it is protected by a patent. A generic reproduces an already known active ingredient once that protection has expired — it is cheaper both to develop and to buy.
Why is drug development a risky investment?
Because a significant share of research never reaches registration: a drug may fail to confirm its efficacy or safety. All the years and funds invested in it are then not recovered.
Issuer profile
What the company does
The company is classified under the «IT, software & pharma» sector, using the taxonomy we apply when comparing securities with one another.
The same sector holds 16 issuers on the platform, and their figures are computed by one method — so this company's revenue, profit and leverage can be compared with them directly.
The company is registered in Russia and identified in regulatory disclosure by tax number 9702034818. That number locates its statements in state registries regardless of how its name is spelled — and the spelling differs even between official documents.
Listed securities
The issuer has 1 security listed: 1 share class. All are shown on this page, including those trading in different modes and different currencies.
Across Moscow Exchange quotation list levels the securities split as follows: 1 at level 2. The level reflects how strict the disclosure, turnover and track-record requirements the issue meets are — not how attractive the investment is.
Financial statements
The most recent annual report we hold is for 2025 under IFRS. The standard is named for a reason: IFRS and RAS compute the same quantities by different rules, disagree by design and are never averaged.
Revenue for 2025 was 37.60B ₽.
That is 74.9 % more than in 2024, when revenue was 21.50B ₽. The comparison stays within one reporting standard — otherwise the growth could turn out to be a change of accounting rules and nothing more.
Net income for 2025 was 7.04B ₽.
Of every unit of revenue, 18.7 % remained as net income. This is the ratio of two figures already named above rather than a separate line from the report: comparing it across companies is meaningful only within one sector and one reporting standard.
Equity stands at 26.30B ₽ against total assets of 71.00B ₽. The difference between the two is the company's liabilities, and the larger it is relative to equity, the more the business depends on borrowed money.
This section is assembled from our own data on the company's securities, dividends and financial statements. It is a description, not a recommendation.